Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
To arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC class I (MHC-I) low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main antitumor host defense, CD8+ T cells. The molecular mechanisms that led to these alterations were incompletely understood. In this study, we identify loss of the transcription factor IRF2 as a frequent underlying mechanism that leads to a tumor immune evasion phenotype in both humans and mice. We identified IRF2 in a CRISPR-based forward genetic screen for genes that controlled MHC-I Ag presentation in HeLa cells. We then found that many primary human cancers, including lung, colon, breast, prostate, and others, frequently downregulated IRF2. Although IRF2 is generally known as a transcriptional repressor, we found that it was a transcriptional activator of many key components of the MHC-I pathway, including immunoproteasomes, TAP, and ERAP1, whose transcriptional control was previously poorly understood. Upon loss of IRF2, cytosol-to–endoplasmic reticulum peptide transport and N-terminal peptide trimming become rate limiting for Ag presentation. In addition, we found that IRF2 is a repressor of PD-L1. Thus, by downregulating a single nonessential gene, tumors become harder to see (reduced Ag presentation), more inhibitory (increased checkpoint inhibitor), and less susceptible to being killed by CD8+ T cells. Importantly, we found that the loss of Ag presentation caused by IRF2 downregulation could be reversed by IFN-stimulated induction of the transcription factor IRF1. The implication of these findings for tumor progression and immunotherapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Irf2 was a transcriptional activator of many key components of the major histocompatibility complex class I antigen presentation. 21”
From Single-Cell RNA Sequencing to Dissect the Immunological Network of Autoimmune Myocarditis. (2020) · cites this paper as [21]
In the citing paper
“A positive correlation between IRF2 expression and MHC I has been observed in many human tumors, including CRC [212].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [212]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 1×
“32 (20) was used to remove 59 or 39 stretches of bases having an average quality of ,20 in a window size of 10.”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231 · cited 1×
“0) (23, 24) with default parameters and a model that specified different replicates as batches.”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 2×
“In addition, sgRNAs were checked for high indel efficiencies in transduced cells by TIDE analysis (17).”
MethodInterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · cited 1×
“It is well established that IRF1 can promote IFN-g–inducible activation of PD-L1 (40, 41).”
BackgroundInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy
Pruitt, K. D., Tatusova, T., Brown, G. R., & Maglott, D. R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1079 · Cited by 1,149 · cited 1×
“Gene quantification was run on the transcriptome (RefSeq v69 downloaded from UCSC Table Browser) (22).”
MethodHarada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T., & Taniguchi, T. (1989) · Cell · doi:10.1016/0092-8674(89)90107-4 · Cited by 958
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2723 · Cited by 846
Self-citationGettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Innate Immune Activity Conditions the Effect of Regulatory Variants upon Monocyte Gene Expression
Fairfax, B. P., Humburg, P., Makino, S., Naranbhai, V., Wong, D., Lau, E., Jostins, L., Plant, K., Andrews, R., McGee, C., et al. (2014) · Science · doi:10.1126/science.1246949 · Cited by 764 · cited 1×
“Additionally, IRF2 regulates the expression of many other genes, as demonstrated by others (58, 59) and shown in this study, such as immunoproteasome subunits, which likely also influence the MHC-I presentation”
BackgroundPorgador, A., Yewdell, J. W., Deng, Y., Bennink, J. R., & Germain, R. N. (1997) · Immunity · doi:10.1016/s1074-7613(00)80447-1 · Cited by 669
ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum
Serwold, T., Gonzalez, F., Kim, J., Jacob, R., & Shastri, N. (2002) · Nature · doi:10.1038/nature01074 · Cited by 628
Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
Street, S. E. A., Cretney, E., & Smyth, M. J. (2001) · Blood · doi:10.1182/blood.v97.1.192 · Cited by 572
An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides
Saric, T., Chang, S.-C., Hattori, A., York, I. A., Markant, S., Rock, K. L., Tsujimoto, M., & Goldberg, A. L. (2002) · Nature Immunology · doi:10.1038/ni859 · Cited by 528
Self-citationPD-L1 Expression in Lung Cancer
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.014 · Cited by 482
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Tanaka, N., Kawakami, T., & Taniguchi, T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.8.4531 · Cited by 423
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01451-3 · Cited by 376
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 315
Mice completely lacking immunoproteasomes show major changes in antigen presentation
Kincaid, E. Z., Che, J. W., York, I., Escobar, H., Reyes-Vargas, E., Delgado, J. C., Welsh, R. M., Karow, M. L., Murphy, A. J., Valenzuela, D. M., et al. (2012) · Nature Immunology · doi:10.1038/ni.2203 · Cited by 289
Self-citationThe expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Sabbatino, F., Villani, V., Yearley, J. H., Deshpande, V., Cai, L., Konstantinidis, I. T., Moon, C., Nota, S., Wang, Y., Al-Sukaini, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0715 · Cited by 216
Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent
Rottman, J. B., Slavin, A. J., Silva, R., Weiner, H. L., Gerard, C. G., & Hancock, W. W. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:8<2372::aid-immu2372>3.0.co;2-d · Cited by 204
Watanabe, N., Sakakibara, J., Hovanessian, A. G., Taniguchi, T., & Fujita, T. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.16.4421 · Cited by 199
Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2
Vaughan, P. S., Aziz, F., van Wijnen, A. J., Wu, S., Harada, H., Taniguchi, T., Soprano, K. J., Stein, J. L., & Stein, G. S. (1995) · Nature · doi:10.1038/377362a0 · Cited by 189
Abele, R., & Tampé, R. (2004) · Physiology · doi:10.1152/physiol.00002.2004 · Cited by 182
Hobart, M., Ramassar, V, Goes, N., Urmson, J., & Halloran, P. F. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.9.4260 · Cited by 163
The regulatory network behind MHC class I expression
Jongsma, M. L. M., Guarda, G., & Spaapen, R. M. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2017.12.005 · Cited by 161
Jesse, T. L., LaChance, R., Iademarco, M. F., & Dean, D. C. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.5.1265 · Cited by 159
Rajapakse, V. N., Luna, A., Yamade, M., Loman, L., Varma, S., Sunshine, M., Iorio, F., Sousa, F. G., Elloumi, F., Aladjem, M. I., et al. (2018) · iScience · doi:10.1016/j.isci.2018.11.029 · Cited by 153
Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma
del Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González‐Aseguinolaza, G., Ruiz‐Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28338 · Cited by 147
Oshima, S., Nakamura, T., Namiki, S., Okada, E., Tsuchiya, K., Okamoto, R., Yamazaki, M., Yokota, T., Aida, M., Yamaguchi, Y., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.14.6298-6310.2004 · Cited by 145
Carretero, R., Romero, J. M., Ruiz-Cabello, F., Maleno, I., Rodriguez, F., Camacho, F. M., Real, L. M., Garrido, F., & Cabrera, T. (2008) · Immunogenetics · doi:10.1007/s00251-008-0303-5 · Cited by 128
Hitting the Target: How T Cells Detect and Eliminate Tumors
Zamora, A. E., Crawford, J. C., & Thomas, P. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701413 · Cited by 121
The Specificity of Trimming of MHC Class I-Presented Peptides in the Endoplasmic Reticulum
Hearn, A. R., York, I. A., & Rock, K. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803663 · Cited by 115
Self-citationENGEL, A. ‐., SVANE, I. M., RYGAARD, J., & WERDELIN, O. (1997) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1997.d01-419.x · Cited by 102
Generation of class I MHC-restricted T-T hybridomas.
Rock, K. L., Rothstein, L., & Gamble, S. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.3.804 · Cited by 84
Self-citationSvane, I. M., Engel, A., Nielsen, M., Ljunggren, H., Rygaard, J., & Werdelin, O. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260827 · Cited by 79
Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18316 · Cited by 75
Rouyez, M.-C., Lestingi, M., Charon, M., Fichelson, S., Buzyn, A., & Dusanter‐Fourt, I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3948 · Cited by 73
Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion
Wu, A., Wu, Q., Deng, Y., Liu, Y., Lu, J., Liu, L., Li, X., Liao, C. L., Zhao, B., & Song, H. X. (2018) · The EMBO Journal · doi:10.15252/embj.201899506 · Cited by 71
Doody, G. M., Stephenson, S., McManamy, C., & Tooze, R. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7614 · Cited by 56
Interferon Regulatory Factor-2 Regulates Cell Growth through Its Acetylation
Masumi, A., Yamakawa, Y., Fukazawa, H., Ozato, K., & Komuro, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213037200 · Cited by 55
Ren, G., Cui, K., Zhang, Z., & Zhao, K. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0007-0 · Cited by 53
Fernandes, D. M., Vidard, L., & Rock, K. L. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000)30:8<2333::aid-immu2333>3.0.co;2-f · Cited by 40
Self-citationMould, A. W., Morgan, M. A. J., Nelson, A., Bikoff, E. K., & Robertson, E. J. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005375 · Cited by 39
Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation
Redondo, M., Ruiz‐Cabello, F., Concha, Á., Cabrera, T., Perez‐Ayala, M., Oliva, M. R., & Garrido, F. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90236-d · Cited by 30
Teo, J., Mirenska, A., Meihui, T., Lee, Y., Oh, J., Hong, L. Z., Wnek, R., Yap, Y. S., Shih, S., Bhagat, A. A. S., et al. (2017) · Future Science OA · doi:10.4155/fsoa-2017-0079 · Cited by 20
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
“, breast, NSCLC, prostate, colorectal, and uterine) downregulate IRF2 expression, which results in an immune evasion phenotype with MHC I low and PD-L1 high expression (69).”
BackgroundInfluentialSelf-citationAntigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Taylor, B. C., & Balko, J. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844866 · Cited by 298
Metadata
- Authors
- Kriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Rock, Kenneth L
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10-01
- Volume
- 203
- Issue
- 7
- Pages
- 1999-2010
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC6761035
- OpenAlex
- W2970242544
- Cited by
- 114
- References
- 64
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 17 · 2023: 23 · 2022: 18 · 2021: 19 · 2020: 10 · 2019: 2
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM107000)
- National Institute of Allergy and Infectious Diseases (R01AI145932, R01AI114495, T32AI095213)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- IRF2, tumor immune evasion, MHC class I antigen presentation, PD-L1, immunoproteasome, TAP, ERAP1, CD8+ T cells, IRF1, interferon-stimulated genes, transcriptional repressor, cancer immunotherapy
- MeSH terms
- HeLa Cells, Humans, Neoplasm Proteins, Neoplasms, Histocompatibility Antigens Class I, Down-Regulation, Gene Expression Regulation, Neoplastic, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Interferon Regulatory Factor-2, HEK293 Cells, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.